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Abstract. A recent paper makes a compelling case for a new mechanism by which 
heterozygous mutations in isocitrate dehydrogenases (IDH1/2) undermine gene 
regulatory mechanisms: 2-hydroxyglutarate (2HG) produced by mutant IDH alters the 
binding of the chromosomal organiser protein CTCF, disrupting the spatial and 
regulatory organisation of the genome.  
 
IDH mutations occur with high frequency in gliomas and other human cancers. Mutant 
IDH enzymes produce the oncometabolite 2HG, which accumulates to high 
concentrations. 2HG not only changes the metabolic state of IDH mutant cells, but - 
crucially - inhibits the activity of enzymes that are critical for chromatin structure and 
gene regulation. Tet enzymes remove DNA methylation [1] and their inhibition by 2HG 
increases DNA methylation in IDH mutant cells. 2HG also inhibits the Jumanji family of 
histone demethylases, increasing histone methylation. These and other effects of 2HG 
[1] perturb gene expression in IDH mutant cells and contribute to tumor formation [1]. 
 
A recent paper [2] adds a new twist to the story by demonstrating that IDH mutations 
affect the binding of the chromatin organiser protein CTCF, which demarcates domains 
of genome folding [3]. To illustrate the relationship between 3D chromatin domains and 
CTCF binding, Figure 1 shows high-resolution Hi-C data (Figure 1A) and CTCF ChIP-
sequencing data (Figure 1B) for the genomic region home to the known glioma 
oncogene, PDGFRA. The PDGFRA promoter is adjacent to CTCF sites in reverse 
orientation (green in Figure 1C). Illustrating an emerging principle of genome folding [3], 
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these reverse sites interact with CTCF motifs in convergent (forward) orientation to form 
a 'loop domain', visible in Hi-C data as a triangle connecting the CTCF sites (Figure 1A). 
 
IDH mutant glioma cells lose ~600 CTCF binding events genome-wide and gain ~300, 
presumably perturbing 3D genome organisation. Loss of CTCF binding correlates with 
increased DNA methylation, and preferentially occurs at CTCF binding sites with motifs 
that contain CG dinucleotides as targets of DNA methylation [2]. DNA methylation may 
not be the only cause of altered CTCF binding in IDH mutant cells: At some sites at least, 
the reported increase in DNA methylation is smaller than the observed drop in CTCF 
binding [2], and increased DNA methylation does not explain the new CTCF binding 
sites that appear in IDH mutant cells. In IDH wild type cells, CTCF binding is sensitive to 
DNA methylation only at a subset of sites, presumably because CTCF co-localises with 
Tet proteins that remove DNA methylation [e.g.4,5]. Tet inhibition in IDH mutant cells 
may increase the sensitivity of CTCF to DNA methylation. Changes in histone 
methylation and other chromatin properties may also contribute to altered CTCF binding 
[1,6]. 
 
In normal cells, genes in the same domain show more similar expression than genes 
located in separate domains, in part because they share access to gene regulatory 
elements [7]. In this way, spatial segmentation of the genome facilitates the regulation of 
gene expression. Does altered CTCF binding perturb the 3D organisation of the genome 
and deregulate gene expression in IDH mutant cells? In support of this idea, the authors 
demonstrate that genes located in separate domains show more similar expression in 
IDH mutant cells than in IDH wild type cells [2]. Until high-resolution Hi-C data for IDH 
mutant cells become available, the precise relationship between altered CTCF binding, 
genome folding, and gene regulation in IDH mutant cells remains speculative. 
Nevertheless, the available data show that in IDH mutant cells the PDGFRA promoter 
interacts with an enhancer near the FIPL1L gene, almost a million base pairs away 
(Figure1), and that PDGFRA expression is upregulated [2]. 
 
The drug 5-azacytidine partially restores CTCF binding and downregulates PDGFRA 
expression in IDH mutant cells [3]. Mechanistically, 5-azacytidine reduces DNA 
methylation by inhibiting the methyl transferase DNMT1, but has additional effects on 
chromatin and gene regulation [8]. To further test the hypothesis that increased 
	 3	
PDGFRA expression in IDH mutant cells is due to reduced CTCF binding, the authors 
mutate a CTCF motif  ('x' in Figure 1A) at the base of the CTCF loop domain adjacent to 
the PDGFRA promoter (Figure 1). Although the deletion of a single motif is distinct from 
the redistribution of CTCF binding in IDH mutant cells (Figure 1), it also results in 
increased interactions of the PDGFRA promoter with the FIPL1L1 enhancer and 
elevated PDGFRA expression. This experiment links CTCF binding to long-range 
interactions and the deregulated expression of a known oncogene in IDH mutant glioma 
[3]. 
 
Closer inspection of the Hi-C data (Figure 1) suggests to us an explanation for the 
sensitivity of PDGFRA to perturbations in CTCF binding. The CTCF sites at the 
PDGFRA promoter interact not just with the convergent CTCF sites at the left boundary 
of the domain, but in addition with other CTCF sites in the region. Such interactions may 
initiate far upstream (far left of PDGFRA), where most CTCF sites are in a forward 
orientation. In the absence of strong CTCF sites in reverse orientation, we imagine that 
loop formation continues towards PDGFRA. It may either be aborted at the forward 
CTCF site ('insulator', Figure 1C) or engage the reverse CTCF site near the PDGFRA 
promoter [9,10] and connect the PDGFRA promoter with CTCF sites in the vicinity of the 
FIPL1L1 enhancer. Such interactions are visible as diagonal lines spanning several 
contact domains in the Hi-C heat map, and also in the interaction track below (Figure 
1A). The FIPL1L1 enhancer itself is bound by CTCF, but does not appear to contact the 
PDGFRA promoter in IDH wild type cells (Figure 1A). Since loops that form in opposite 
directions are thought to compete with each other [10], weakened CTCF binding in IDH 
mutant cells, or the CRISPR-mediated deletion of a CTCF site at the left boundary of the 
loop domain next to PDGFRA, may increase contacts between the PDGFRA promoter 
and FIPL1L enhancer.  
 
Clinically, high levels of 2HG may sensitise IDH-mutant tumour cells to other therapeutic 
approaches [1]. Alternatively, pharmacological inhibition of IDH, or selective inhibition of 
the abnormal enzymatic activity could be used to specifically target tumour cells [1]. IDH 
inhibitors can revert the impact of IDH mutations on chromatin state [6]. Whether this 
includes correction of CTCF binding, genome folding and gene expression is an 
interesting question that remains to be explored. 
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Figure legend 
 
Figure 1. Chromosome folding across the PDGFRA region: mechanisms and models. 
A. Hi-C heat map of the 3D chromatin organisation around PDGFRA. Red indicates 
increased interactions. Triangular shapes are contact domains. Diagonal lines 
emanating from triangles indicate interactions that span several domains. The line below 
the heat map shows interactions from the viewpoint of the PDGFRA promoter. The 
genomic positions of the PDGFRA promoter, a putative insulator, and the FIPL1L 
enhancer are shown underneath. 
B. CTCF binding data from ChIP-seq experiments. Peak height reflects occupancy. 
Glioma cells GSC4 and GBM2w are IDH wt, GSC119 and AA15m are IDH mutant. 
C. The direction of CTCF motif sequence (https://github.com/liz-is/ctcf-motif-imr90) is 
indicated as forward (red) or reverse (green). Motifs with low CTCF occupancy are 
omitted for clarity. Note that CTCF binding marks domain boundaries. Strong 
interactions (horizontal lines) form between the forward CTCF sites at the insulator and 
the reverse CTCF sites at the PDGFRA promoter. A cartoon illustrates how current 
models envisage the formation of this domain by the extrusion of a chromatin loop 
through a ring-shaped complex, possibly cohesin [9,10]. Extrusion stops when it 
encounters occupied convergent CTCF sites. Interactions between forward CTCF sites 
near the FIPL1L enhancer with reverse CTCF sites at the PDGFRA promoter may form 
as illustrated by the cartoon below: Loop extrusion that starts between CTCF sites in the 
same orientation, it is thought to skip CTCF sites until a reverse site is reached [9,10]. 
Hi-C data suggests that loop extrusion skips the weak reverse site in pale green and 
continue towards the PDGFRA promoter.  
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